Cosmax joins Harvard-affiliated hospital network to pursue anti-aging, metabolic research

Cosmax Group, a Korean cosmetics manufacturer, has entered into a partnership with Mass General Brigham (MGB), a Harvard-affiliated hospital network, to expand its research focus into medical and biotechnology fields. This move aims to develop treatments and health products for aging, weight management, and metabolic health. The collaboration, known as the VIVA project, builds upon previous research conducted between 2024 and 2026 that discovered a substance derived from specific microorganisms can alleviate symptoms of atopic dermatitis and enhance skin barrier function.

The findings of this research were published in the international journal Allergy, and Cosmax has filed a patent application for the related microbial technology. During the second phase of the partnership, which spans from 2026 to 2029, Cosmax and MGB plan to extend their research beyond cosmetics to explore functional ingredients for health supplements and potential drug candidates.

Brief written by urgent.news from The Korea Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.